Fig. 2From: An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)Discordant T cell phenotypes in the tumor compared to circulating lymphocytes. (a) Summary of paired tumor and PBMC CD4 and CD8 T cell phenotyping for 4-1BB, TIGIT, and PD-1 at baseline. (b) Representative FACS of paired peripheral blood mononuclear cells and tumor biopsies. *P < 0.05, ** P < 0.01, *** P < 0.001Back to article page